Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.

MLA

Ismail, Rawa K., et al. “Long-Term Survival of Patients with Advanced Melanoma Treated with BRAF-MEK Inhibitors.” Melanoma Research, vol. 32, no. 6, Dec. 2022, pp. 460–68. EBSCOhost, https://doi.org/10.1097/CMR.0000000000000832.

APA

Ismail, R. K., Suijkerbuijk, K. P. M., de Boer, A., van Dartel, M., Hilarius, D. L., Pasmooij, A. M. G., van Zeijl, M. C. T., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., van der Veldt, A. A. M., Vreugdenhil, A., … Wouters, M. W. J. M. (2022). Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research, 32(6), 460–468. https://doi.org/10.1097/CMR.0000000000000832

Chicago

Ismail, Rawa K, Karijn P M Suijkerbuijk, Anthonius de Boer, Maaike van Dartel, Doranne L Hilarius, A M G Pasmooij, Michiel C T van Zeijl, et al. 2022. “Long-Term Survival of Patients with Advanced Melanoma Treated with BRAF-MEK Inhibitors.” Melanoma Research 32 (6): 460–68. doi:10.1097/CMR.0000000000000832.